Randy Kauk
Acute Care · Scottsdale, AZNPI 1982131702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,086, 4.2 times the $493 reported in 2021.
Across 83 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$571
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$556
- Corium, LLC$426
- Vanda Pharmaceuticals Inc.$409
- Galderma Laboratories, L.p.$378
- Alkermes, Inc.$228
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,664100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 27 | $571 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $556 |
| Corium, LLC | 13 | $426 |
| Vanda Pharmaceuticals Inc. | 4 | $409 |
| Galderma Laboratories, L.p. | 4 | $378 |
| Alkermes, Inc. | 3 | $228 |
| AbbVie | 2 | $197 |
| Merz North America, Inc. | 1 | $169 |
| Otsuka America Pharmaceutical, Inc. | 3 | $156 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Neurocrine Biosciences, Inc. | 1 | $118 |
| Boston Scientific | 3 | $116 |
| Lundbeck LLC | 3 | $54 |
| Almatica Pharma LLC | 2 | $39 |
| Novo Nordisk | 2 | $32 |
| Abbott | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$496
- LYBALVI$404
- Fanapt$376
- XEOMIN$169
- Azstarys$125
- VRAYLAR$125
- COBENFY$123
- REXULTI$121
- INGREZZA$118
- Dyanavel XR$108
- Quillivant$108
- Quillichew ER$108
- ENTRADA$102
How this compares
$3,676 in reported general payments places this provider in the 85th percentile of 482 acute care providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $9,463 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 55 | $1,809 |
Paid to pharmacies, not to this prescriber.
Other acute care in Scottsdale
- Stephanie WilsonScottsdale$37K
- Cynthia CarstenScottsdale$9K
- Tamera QuerreyScottsdale$7K
- Damaris HazellScottsdale$5K
- Krupa PatelScottsdale$5K
- Nicole CiffoneTucson$162K
- Kim KrmpoticPhoenix$79K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.